Developer docs
API playgroundTry for free, no card

Search company profiles

Mesoblast

Full company profile

uuid0000qjr

Namestring
Mesoblast
Legal namestring
Mesoblast Ltd.
Websiteurl
mesoblast.com
Company typeenum
Public
Founded yearint
2004
Descriptiontext

Mesoblast Limited is a commercial-stage biotechnology company founded in 2004 by physician scientist Silviu Itescu and dual-listed on the ASX (MSB) and NASDAQ (MESO). The company develops allogeneic (off-the-shelf) cellular medicines derived from a proprietary mesenchymal lineage cell (MLC) platform sourced from healthy adult donor bone marrow. These cells are expanded at industrial scale using proprietary media formulations and 2D/3D bioreactor technology, yielding cryopreserved cellular products that can be administered without donor-recipient matching or recipient immune suppression.

The company's commercial product is Ryoncil (remestemcel-L-rknd), the first FDA-approved mesenchymal stromal cell therapy for any indication, approved in December 2024 and commercially launched in April 2025 for pediatric steroid-refractory acute graft-versus-host disease (SR-aGvHD). Ryoncil generated approximately US$100 million in cumulative net revenues within its first year of launch, with Q3 FY2026 net revenues of US$30.3 million and full-year FY2026 guidance of US$110-120 million at 93% gross margin. The late-stage pipeline includes Revascor (rexlemestrocel-L) for chronic heart failure, MPC-06-ID for chronic discogenic low back pain, MPC-25-Osteo for spinal fusion, MPC-300-IV for biologic-refractory rheumatoid arthritis and diabetic nephropathy, and an expanding set of indications including adult SR-aGvHD and Duchenne muscular dystrophy.

Mesoblast monetizes through direct U.S. sales of Ryoncil to transplant centers, supplemented by licensing and royalty revenue from international partners including JCR Pharmaceuticals (Japan/TEMCELL), Grunenthal (Europe/Latin America), Tasly (China), and Takeda (Alofisel). In April 2026, the company acquired an exclusive worldwide license to a CAR technology platform from Mayo Clinic to engineer targeted MSC products for inflammatory and autoimmune diseases. The company operates from Melbourne, Australia with U.S. operations in New York and process development in Singapore, supported by a long-term manufacturing alliance with Lonza.

Short descriptiontext

Mesoblast is a commercial-stage biotech developing allogeneic off-the-shelf mesenchymal lineage cell therapies for severe inflammatory conditions. Its FDA-approved Ryoncil treats pediatric SR-aGvHD, with a late-stage pipeline targeting heart failure, chronic low back pain, and autoimmune diseases.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersMelbourne, Australia
HQ citystring
Melbourne
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
allogeneic cell therapy, regenerative medicine, mesenchymal stromal cells, cellular medicines, biologic therapeutics
Industry6 codes
PRIMARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAKAC
Cell Therapy Manufacturing Services (GMP, autologous/allogeneic)
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAIAAAO
Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Regenerative Medicine Cellular Therapies
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Ryoncil Product Sales
TypeOne Time License
Description

Commercial revenue from FDA-approved product Ryoncil (remestemcel-L-rknd) for pediatric SR-aGvHD. Launched April 2025, generating $48.7M net revenue in H1 FY2026 with 93% gross margin. Full-year FY2026 guidance of $110-120M net revenue.

stocktitan.net
2Licensing and Royalty Revenue
TypeLicensing Royalties
Description

JCR Pharmaceuticals in Japan receives royalties on TEMCELL sales; potential milestones from Grunenthal (Europe/Latin America MPC-06-ID), Tasly (China Revascor/MPC-25-IC), and Takeda (Alofisel) with up to €20M plus royalties.

mesoblast.com
3CAR Technology Licensing
TypeLicensing Royalties
Description

Mayo Clinic received shares as consideration for exclusive worldwide CAR technology license, with ongoing in-kind support including GMP manufacturing activities.

globenewswire.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Ryoncil
Description

FDA-approved mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease in pediatric patients

mesoblast.com
+3 more records
Core offering1 text field

Mesoblast develops, manufactures, and commercializes allogeneic (off-the-shelf) cellular medicines based on proprietary mesenchymal lineage cell (MLC) technology for severe and life-threatening inflammatory conditions. Its marketed product, Ryoncil (remestemcel-L-rknd), is the first FDA-approved mesenchymal stromal cell therapy, indicated for steroid-refractory acute graft-versus-host disease in pediatric patients and commercially launched in the United States in April 2025. The company also advances a late-stage pipeline including Revascor for chronic heart failure and MPC-06-ID for chronic discogenic low back pain.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Day-28 overall response rate of 66% (204/309 patients) in pediatric SR-aGvHD
+5 more records
Product overview1 text field

Mesoblast is a commercial-stage biotechnology company and world leader in developing allogeneic (off-the-shelf) cellular medicines for severe and life-threatening inflammatory conditions. The company's proprietary mesenchymal lineage cell technology platform yields industrial-scale, cryopreserved, off-the-shelf cellular medicines that can be administered without donor-recipient matching or recipient immune suppression. The marketed product portfolio centers on Ryoncil (remestemcel-L-rknd), the first FDA-approved mesenchymal stromal cell therapy for pediatric SR-aGvHD, launched commercially in April 2025. The late-stage pipeline includes Revascor (rexlemestrocel-L) for chronic heart failure, MPC-06-ID (rexlemestrocel-L) for chronic discogenic low back pain, MPC-300-IV for biologic-refractory rheumatoid arthritis and diabetic nephropathy, MPC-25-Osteo for spinal fusion, and MPC-25-IC for acute myocardial infarction. In April 2026, Mesoblast acquired an exclusive worldwide license to a CAR technology platform from Mayo Clinic to enhance targeted homing of its MSC products for autoimmune and inflammatory diseases.

Product and service8 records
1Ryoncil (remestemcel-L-rknd)
CategoryCellular Medicine - Oncology/Hematology
Description

FDA-approved allogeneic mesenchymal stromal cell therapy indicated for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGvHD) in pediatric patients 2 months of age and older; the first MSC product approved by the US FDA for any indication, administered intravenously at 2 x 10^6 MSCs/kg twice weekly for four consecutive weeks.

2Revascor (rexlemestrocel-L)
CategoryCellular Medicine - Cardiovascular
Description

Phase 3 product candidate consisting of 150 million mesenchymal precursor cells administered by direct injection into heart muscle for treatment of advanced and end-stage chronic heart failure, targeting cardiac inflammation to improve heart failure outcomes.

3MPC-06-ID (rexlemestrocel-L)
CategoryCellular Medicine - Spine/Orthopedic
Description

Phase 3 product candidate consisting of 6 million mesenchymal precursor cells injected directly into damaged intervertebral discs for treatment of chronic low back pain caused by disc degeneration, targeting disc inflammation and aiming to restore disc function.

4MPC-25-Osteo
CategoryCellular Medicine - Spine/Orthopedic
Description

Phase 3-ready product candidate consisting of 25 million mesenchymal precursor cells delivered on a collagen ceramic carrier material for lumbar spinal fusion procedures.

5MPC-25-IC
CategoryCellular Medicine - Cardiovascular
Description

Phase 2 product candidate for treatment of acute myocardial infarction via intracoronary infusion, delivered during angioplasty procedures to protect at-risk heart muscle cells from dying.

6MPC-300-IV
CategoryCellular Medicine - Immune-Mediated/Inflammatory
Description

Phase 2 product candidate comprising 300 million mesenchymal precursor cells delivered intravenously for treatment of biologic-refractory rheumatoid arthritis and diabetic nephropathy, targeting multiple inflammatory pathways simultaneously.

7remestemcel-L for Crohn's Disease
CategoryCellular Medicine - Immune-Mediated/Inflammatory
Description

Tier 2 product candidate consisting of 100-200 million mesenchymal stem cells delivered intravenously for treatment of Crohn's disease refractory to steroids and immunosuppressants, targeting T-cell mediated inflammatory responses.

8MPC-300-IV for Diabetic Nephropathy
CategoryCellular Medicine - Immune-Mediated/Inflammatory
Description

Phase 2 product candidate targeting diabetic kidney disease through intravenous delivery of up to 300 million mesenchymal precursor cells, addressing inflammatory pathways involved in renal complications of type 2 diabetes.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

JCR has exclusive rights in Japan to Mesoblast's technology for hematologic malignancies using hematopoietic stem cell transplants. Received Japanese Government regulatory approval for TEMCELL HS Inj., the first allogeneic cell-based product to receive full approval in Japan. Expanded partnership in 2018 to cover wound healing in Epidermolysis Bullosa patients.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic partnership to develop and commercialize MPC-06-ID for chronic low back pain in Europe and Latin America. Companies agreed on development plan for European regulatory requirements, collaborating on Phase 3 trial design with results expected to support both FDA and EMA approvals.

3Tasly Pharmaceutical Group
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Tasly has rights in China to develop, manufacture and commercialize Revascor for chronic heart failure and MPC-25-IC for acute myocardial infarction. Parties plan to leverage each other's clinical trial results to expedite regulatory submissions.

mesoblast.com
Strategic tierCoreTypeTechnology or Integration
Description

Long-term commercial manufacturing alliance providing capacity for global supply of proprietary product candidates. Access to Lonza's cell therapy facilities in Singapore, with potential for purpose-built facility to meet long-term commercial objectives.

Strategic tierCoreTypeTechnology or Integration
Description

Mesoblast acquired exclusive worldwide license to patented CAR technology platform from Mayo Clinic, published in Nature Biomedical Engineering. CAR technology enhances MSC products for targeted homing to inflamed tissue. Mayo Clinic provides in-kind support including GMP manufacturing activities.

6Blood and Marrow Transplant Clinical Trials Network (BMT CTN)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaborative partnership to initiate pivotal Phase 3 trial of Ryoncil for adults with severe acute GVHD refractory to corticosteroids. Enrollment expected to begin Q1 2026. Trial aims to extend Ryoncil from pediatric to adult indication.

biospace.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Patient advocacy collaboration supporting Ryoncil registrational trial in Duchenne muscular dystrophy. Partnership includes patient identification and trial awareness support through the Duchenne Registry.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Athersys
TypeDirect peer
Description

Athersys developed MultiStem, an allogeneic bone marrow-derived multipotent adult progenitor cell therapy targeting inflammatory conditions including GvHD and ischemic stroke. It is a direct allogeneic cell therapy peer to Mesoblast's Ryoncil platform, with comparable off-the-shelf manufacturing and similar target indications.

2Pluristem Therapeutics
TypeDirect peer
Description

Pluristem develops allogeneic placenta-derived mesenchymal-like adherent stromal cell therapies (PLX cells) for inflammatory and ischemic conditions. Direct cell therapy peer with shared allogeneic, off-the-shelf approach overlapping Mesoblast's indication strategy in GvHD and peripheral artery disease.

TypeEmerging player
Description

Fate Therapeutics develops off-the-shelf iPSC-derived NK and T-cell immunotherapies primarily for oncology. Emerging player in the broader allogeneic cell therapy space with similar industrialization, GMP manufacturing, and pipeline-expansion approach but different modality (engineered immune cells vs. MSC).

TypeDirect peer
Description

JCR Pharmaceuticals commercializes Mesoblast's remestemcel-L as TEMCELL HS Inj. in Japan for acute GvHD — the first allogeneic cell therapy fully approved in Japan. As Mesoblast's exclusive Japan licensee, JCR is both partner and direct commercial peer in the same MSC product.

TypeBroad incumbent
Description

Takeda acquired TiGenix and commercializes Alofisel, a competing allogeneic MSC therapy for complex perianal fistulas in Crohn's disease. As a major pharmaceutical incumbent and Mesoblast's licensor-counterparty on Alofisel royalties, Takeda is a broad incumbent peer in the cell therapy space.

TypeBroad incumbent
Description

Vertex Pharmaceuticals is a broad incumbent in advanced therapies through its Casgevy partnership with CRISPR Therapeutics (first FDA-approved CRISPR gene therapy). While focused on gene editing rather than MSC, Vertex is a relevant commercial-stage advanced-therapy peer for capital allocation and pricing-power comparisons.

7Bluebird Bio
TypeDirect peer
Description

Bluebird Bio develops gene and cell therapies for severe genetic diseases and oncology. Direct peer in commercial/clinical-stage advanced therapy with similar high-cost, single-administration pricing models and rare-disease commercialization playbook.

TypeEmerging player
Description

Adaptimmune develops engineered T-cell receptor (TCR) therapies for solid tumors. Emerging player in cell-based therapy commercialization with overlapping regulatory, manufacturing, and pricing considerations but different modality.

TypeDirect peer
Description

Atara developed tabelecleucel, an allogeneic T-cell immunotherapy for Epstein-Barr virus-driven diseases including post-transplant lymphoproliferative disease, with overlap in the transplant/immunocompromised patient setting served by Ryoncil.

TypeEmerging player
Description

CRISPR Therapeutics pioneered CRISPR/Cas9 gene-editing therapies (Casgevy, co-developed with Vertex) for sickle cell disease and beta-thalassemia. Emerging peer in the broader cell and gene therapy category with shared GMP manufacturing and regulatory pathway considerations.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mesoblast

Regenerative Medicine Cellular Therapiesmesoblast.com

Mesoblast is a commercial-stage biotech developing allogeneic off-the-shelf mesenchymal lineage cell therapies for severe inflammatory conditions. Its FDA-approved Ryoncil treats pediatric SR-aGvHD, with a late-stage pipeline targeting heart failure, chronic low back pain, and autoimmune diseases.

What Mesoblast does

Mesoblast Limited is a commercial-stage biotechnology company founded in 2004 by physician scientist Silviu Itescu and dual-listed on the ASX (MSB) and NASDAQ (MESO). The company develops allogeneic (off-the-shelf) cellular medicines derived from a proprietary mesenchymal lineage cell (MLC) platform sourced from healthy adult donor bone marrow. These cells are expanded at industrial scale using proprietary media formulations and 2D/3D bioreactor technology, yielding cryopreserved cellular products that can be administered without donor-recipient matching or recipient immune suppression.

The company's commercial product is Ryoncil (remestemcel-L-rknd), the first FDA-approved mesenchymal stromal cell therapy for any indication, approved in December 2024 and commercially launched in April 2025 for pediatric steroid-refractory acute graft-versus-host disease (SR-aGvHD). Ryoncil generated approximately US$100 million in cumulative net revenues within its first year of launch, with Q3 FY2026 net revenues of US$30.3 million and full-year FY2026 guidance of US$110-120 million at 93% gross margin. The late-stage pipeline includes Revascor (rexlemestrocel-L) for chronic heart failure, MPC-06-ID for chronic discogenic low back pain, MPC-25-Osteo for spinal fusion, MPC-300-IV for biologic-refractory rheumatoid arthritis and diabetic nephropathy, and an expanding set of indications including adult SR-aGvHD and Duchenne muscular dystrophy.

Mesoblast monetizes through direct U.S. sales of Ryoncil to transplant centers, supplemented by licensing and royalty revenue from international partners including JCR Pharmaceuticals (Japan/TEMCELL), Grunenthal (Europe/Latin America), Tasly (China), and Takeda (Alofisel). In April 2026, the company acquired an exclusive worldwide license to a CAR technology platform from Mayo Clinic to engineer targeted MSC products for inflammatory and autoimmune diseases. The company operates from Melbourne, Australia with U.S. operations in New York and process development in Singapore, supported by a long-term manufacturing alliance with Lonza.

Mesoblast firmographics

Firmographics
Name
Mesoblast
Legal name
Mesoblast Ltd.
Website
https://mesoblast.com
Company type
Public
Founded year
2004
Operating status
Operating
Headcount range
101–250 employees
Short description
Mesoblast is a commercial-stage biotech developing allogeneic off-the-shelf mesenchymal lineage cell therapies for severe inflammatory conditions. Its FDA-approved Ryoncil treats pediatric SR-aGvHD, with a late-stage pipeline targeting heart failure, chronic low back pain, and autoimmune diseases.
Ownership category
akta.pro rank

Mesoblast industry classification

Industry
Product category
Regenerative Medicine Cellular Therapies
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAKAC
Cell Therapy Manufacturing Services (GMP, autologous/allogeneic)
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAIAAAO
Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Allogeneic cell therapy
  • Regenerative medicine
  • Mesenchymal stromal cells
  • Cellular medicines
  • Biologic therapeutics

Where Mesoblast is headquartered

Location

Headquarters

HQ city
Melbourne
HQ country
Australia
HQ region
Oceania

Offices3 records

Markets served

Mesoblast business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Ryoncil Product Sales: Commercial revenue from FDA-approved product Ryoncil (remestemcel-L-rknd) for pediatric SR-aGvHD. Launched April 2025, generating $48.7M net revenue in H1 FY2026 with 93% gross margin. Full-year FY2026 guidance of $110-120M net revenue.
  2. Licensing and Royalty Revenue: JCR Pharmaceuticals in Japan receives royalties on TEMCELL sales; potential milestones from Grunenthal (Europe/Latin America MPC-06-ID), Tasly (China Revascor/MPC-25-IC), and Takeda (Alofisel) with up to €20M plus royalties.
  3. CAR Technology Licensing: Mayo Clinic received shares as consideration for exclusive worldwide CAR technology license, with ongoing in-kind support including GMP manufacturing activities.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Mesoblast product offering

Product offering

Core offering

Mesoblast develops, manufactures, and commercializes allogeneic (off-the-shelf) cellular medicines based on proprietary mesenchymal lineage cell (MLC) technology for severe and life-threatening inflammatory conditions. Its marketed product, Ryoncil (remestemcel-L-rknd), is the first FDA-approved mesenchymal stromal cell therapy, indicated for steroid-refractory acute graft-versus-host disease in pediatric patients and commercially launched in the United States in April 2025. The company also advances a late-stage pipeline including Revascor for chronic heart failure and MPC-06-ID for chronic discogenic low back pain.

Product overview

Mesoblast is a commercial-stage biotechnology company and world leader in developing allogeneic (off-the-shelf) cellular medicines for severe and life-threatening inflammatory conditions. The company's proprietary mesenchymal lineage cell technology platform yields industrial-scale, cryopreserved, off-the-shelf cellular medicines that can be administered without donor-recipient matching or recipient immune suppression. The marketed product portfolio centers on Ryoncil (remestemcel-L-rknd), the first FDA-approved mesenchymal stromal cell therapy for pediatric SR-aGvHD, launched commercially in April 2025. The late-stage pipeline includes Revascor (rexlemestrocel-L) for chronic heart failure, MPC-06-ID (rexlemestrocel-L) for chronic discogenic low back pain, MPC-300-IV for biologic-refractory rheumatoid arthritis and diabetic nephropathy, MPC-25-Osteo for spinal fusion, and MPC-25-IC for acute myocardial infarction. In April 2026, Mesoblast acquired an exclusive worldwide license to a CAR technology platform from Mayo Clinic to enhance targeted homing of its MSC products for autoimmune and inflammatory diseases.

Differentiator

Problem solved

Functional benefit

Brands

  • Ryoncil: FDA-approved mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease in pediatric patients
  • Revascor
  • MPC-06-ID
  • TEMCELL

Products and services

  • Ryoncil (remestemcel-L-rknd) FDA-approved allogeneic mesenchymal stromal cell therapy indicated for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGvHD) in pediatric patients 2 months of age and older; the first MSC product approved by the US FDA for any indication, administered intravenously at 2 x 10^6 MSCs/kg twice weekly for four consecutive weeks.
  • Revascor (rexlemestrocel-L) Phase 3 product candidate consisting of 150 million mesenchymal precursor cells administered by direct injection into heart muscle for treatment of advanced and end-stage chronic heart failure, targeting cardiac inflammation to improve heart failure outcomes.
  • MPC-06-ID (rexlemestrocel-L) Phase 3 product candidate consisting of 6 million mesenchymal precursor cells injected directly into damaged intervertebral discs for treatment of chronic low back pain caused by disc degeneration, targeting disc inflammation and aiming to restore disc function.
  • MPC-25-Osteo Phase 3-ready product candidate consisting of 25 million mesenchymal precursor cells delivered on a collagen ceramic carrier material for lumbar spinal fusion procedures.
  • MPC-25-IC Phase 2 product candidate for treatment of acute myocardial infarction via intracoronary infusion, delivered during angioplasty procedures to protect at-risk heart muscle cells from dying.
  • MPC-300-IV Phase 2 product candidate comprising 300 million mesenchymal precursor cells delivered intravenously for treatment of biologic-refractory rheumatoid arthritis and diabetic nephropathy, targeting multiple inflammatory pathways simultaneously.
  • remestemcel-L for Crohn's Disease Tier 2 product candidate consisting of 100-200 million mesenchymal stem cells delivered intravenously for treatment of Crohn's disease refractory to steroids and immunosuppressants, targeting T-cell mediated inflammatory responses.
  • MPC-300-IV for Diabetic Nephropathy Phase 2 product candidate targeting diabetic kidney disease through intravenous delivery of up to 300 million mesenchymal precursor cells, addressing inflammatory pathways involved in renal complications of type 2 diabetes.

Quantifiable outcome

  • Day-28 overall response rate of 66% (204/309 patients) in pediatric SR-aGvHD
  • +5 more outcomes

Companies that use Mesoblast

Customer profile

Named customers1 record

Segments5 records

Ideal customer profiles5 records

Mesoblast technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Mesoblast partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core.

  • JCR Pharmaceuticals Co. LtdcoreStrategic or Co-development Partner · 1 January 2018JCR has exclusive rights in Japan to Mesoblast's technology for hematologic malignancies using hematopoietic stem cell transplants. Received Japanese Government regulatory approval for TEMCELL HS Inj., the first allogeneic cell-based product to receive full approval in Japan. Expanded partnership in 2018 to cover wound healing in Epidermolysis Bullosa patients.
  • Grunenthal GmbHcoreStrategic or Co-development PartnerStrategic partnership to develop and commercialize MPC-06-ID for chronic low back pain in Europe and Latin America. Companies agreed on development plan for European regulatory requirements, collaborating on Phase 3 trial design with results expected to support both FDA and EMA approvals.
  • Tasly Pharmaceutical GroupcoreStrategic or Co-development PartnerTasly has rights in China to develop, manufacture and commercialize Revascor for chronic heart failure and MPC-25-IC for acute myocardial infarction. Parties plan to leverage each other's clinical trial results to expedite regulatory submissions.
  • Lonza GroupcoreTechnology or IntegrationLong-term commercial manufacturing alliance providing capacity for global supply of proprietary product candidates. Access to Lonza's cell therapy facilities in Singapore, with potential for purpose-built facility to meet long-term commercial objectives.
  • Mayo CliniccoreTechnology or IntegrationMesoblast acquired exclusive worldwide license to patented CAR technology platform from Mayo Clinic, published in Nature Biomedical Engineering. CAR technology enhances MSC products for targeted homing to inflamed tissue. Mayo Clinic provides in-kind support including GMP manufacturing activities.
  • Blood and Marrow Transplant Clinical Trials Network (BMT CTN)coreStrategic or Co-development PartnerCollaborative partnership to initiate pivotal Phase 3 trial of Ryoncil for adults with severe acute GVHD refractory to corticosteroids. Enrollment expected to begin Q1 2026. Trial aims to extend Ryoncil from pediatric to adult indication.
  • Parent Project Muscular DystrophycoreStrategic or Co-development PartnerPatient advocacy collaboration supporting Ryoncil registrational trial in Duchenne muscular dystrophy. Partnership includes patient identification and trial awareness support through the Duchenne Registry.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Mesoblast competitors and assessment

Company assessment

Direct peers

  • Athersys: Athersys developed MultiStem, an allogeneic bone marrow-derived multipotent adult progenitor cell therapy targeting inflammatory conditions including GvHD and ischemic stroke. It is a direct allogeneic cell therapy peer to Mesoblast's Ryoncil platform, with comparable off-the-shelf manufacturing and similar target indications.
  • Pluristem Therapeutics: Pluristem develops allogeneic placenta-derived mesenchymal-like adherent stromal cell therapies (PLX cells) for inflammatory and ischemic conditions. Direct cell therapy peer with shared allogeneic, off-the-shelf approach overlapping Mesoblast's indication strategy in GvHD and peripheral artery disease.
  • JCR Pharmaceuticals: JCR Pharmaceuticals commercializes Mesoblast's remestemcel-L as TEMCELL HS Inj. in Japan for acute GvHD — the first allogeneic cell therapy fully approved in Japan. As Mesoblast's exclusive Japan licensee, JCR is both partner and direct commercial peer in the same MSC product.
  • Bluebird Bio: Bluebird Bio develops gene and cell therapies for severe genetic diseases and oncology. Direct peer in commercial/clinical-stage advanced therapy with similar high-cost, single-administration pricing models and rare-disease commercialization playbook.
  • Atara Biotherapeutics: Atara developed tabelecleucel, an allogeneic T-cell immunotherapy for Epstein-Barr virus-driven diseases including post-transplant lymphoproliferative disease, with overlap in the transplant/immunocompromised patient setting served by Ryoncil.

Emerging players

  • Fate Therapeutics: Fate Therapeutics develops off-the-shelf iPSC-derived NK and T-cell immunotherapies primarily for oncology. Emerging player in the broader allogeneic cell therapy space with similar industrialization, GMP manufacturing, and pipeline-expansion approach but different modality (engineered immune cells vs. MSC).
  • Adaptimmune Therapeutics: Adaptimmune develops engineered T-cell receptor (TCR) therapies for solid tumors. Emerging player in cell-based therapy commercialization with overlapping regulatory, manufacturing, and pricing considerations but different modality.
  • CRISPR Therapeutics: CRISPR Therapeutics pioneered CRISPR/Cas9 gene-editing therapies (Casgevy, co-developed with Vertex) for sickle cell disease and beta-thalassemia. Emerging peer in the broader cell and gene therapy category with shared GMP manufacturing and regulatory pathway considerations.

Broad incumbents

  • Takeda Pharmaceutical: Takeda acquired TiGenix and commercializes Alofisel, a competing allogeneic MSC therapy for complex perianal fistulas in Crohn's disease. As a major pharmaceutical incumbent and Mesoblast's licensor-counterparty on Alofisel royalties, Takeda is a broad incumbent peer in the cell therapy space.
  • Vertex Pharmaceuticals: Vertex Pharmaceuticals is a broad incumbent in advanced therapies through its Casgevy partnership with CRISPR Therapeutics (first FDA-approved CRISPR gene therapy). While focused on gene editing rather than MSC, Vertex is a relevant commercial-stage advanced-therapy peer for capital allocation and pricing-power comparisons.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Mesoblast social profiles

Digital presence

Mesoblast financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mesoblast leadership team

Management profile

Number of profiles

Profiles13 records

Mesoblast subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Mesoblast funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mesoblast M&A and investment

M&A and investment

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mesoblast

What does Mesoblast do?

Mesoblast develops, manufactures, and commercializes allogeneic (off-the-shelf) cellular medicines based on proprietary mesenchymal lineage cell (MLC) technology for severe and life-threatening inflammatory conditions. Its marketed product, Ryoncil (remestemcel-L-rknd), is the first FDA-approved mesenchymal stromal cell therapy, indicated for steroid-refractory acute graft-versus-host disease in pediatric patients and commercially launched in the United States in April 2025. The company also advances a late-stage pipeline including Revascor for chronic heart failure and MPC-06-ID for chronic discogenic low back pain.

Is Mesoblast a public or private company?

Mesoblast is a public company. It is classified as public and is currently operating.

When was Mesoblast founded?

Mesoblast was founded in 2004. It employs 101 to 250 people.

Where is Mesoblast based?

Mesoblast is headquartered in Melbourne, Australia, in the Oceania region.

How does Mesoblast make money?

Three revenue lines are on record. Ryoncil Product Sales are the primary driver. The others are licensing and Royalty Revenue and CAR Technology Licensing.

Who are Mesoblast's main competitors?

Direct peers on record are Athersys, Pluristem Therapeutics, JCR Pharmaceuticals, Bluebird Bio and Atara Biotherapeutics. Emerging players are Fate Therapeutics, Adaptimmune Therapeutics and CRISPR Therapeutics. Broad incumbents are Takeda Pharmaceutical and Vertex Pharmaceuticals.

Does Mesoblast have an API?

No public API is recorded for Mesoblast.

What industry is Mesoblast in?

Mesoblast's product category is Regenerative Medicine Cellular Therapies. Its primary akta.pro industry code is HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf), with a secondary code of HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewMSB: RYONCIL sales fund a pipeline with key 2027 readouts and potential filingsMesoblast Limited reported FY26 revenue of $115M and advanced RYONCIL's commercial and adult GVHD and Duchenne programs. A 350-patient low-back-pain trial is expected to read out around mid-2027, with cardiovascular plans including a potential LVAD-related filing and pulmonary hypertension development.Investing.comMesoblast stock hits 52-week low at 11.89 USDMesoblast Ltd ADR stock hit a 52-week low of $11.89, down 11% over the past week and 31% year-to-date. The company reported $115 million in fiscal 2026 revenue, its first full commercial year, with Q4 revenue of $36 million. Analysts set price targets between $35 and $39, citing undervaluation.YahooTop 3 Australian Founder Led Stocks To Watch In November 2026Three founder-led Australian stocks—Flight Centre Travel Group, Mesoblast, and Harvey Norman Holdings—are highlighted for November 2026. Flight Centre has a market cap of A$2.44b, Mesoblast A$2.51b, and Harvey Norman A$5.57b. The article notes that each company's earnings power depends on unresolved operational pressures.FinanzNachrichten.deJohnson & Johnson erzielt 710 Millionen Dollar mit Zelltherapie - Mesoblast stellt neue CAR-Technologie vorJohnson & Johnson and Legend Biotech reported $710 million net revenue from Carvykti in Q3 2026, a 36% increase, with international sales up 86%. Mesoblast presented a new CAR-MSC platform targeting inflammatory diseases like lupus and IBD, with no clinical data yet.Simply Wall StAustralian Founder Run Stocks To Own In November 2026Three Australian founder-led stocks—Flight Centre Travel Group, Pro Medicus, and Mesoblast—are highlighted for November 2026, with market caps of A$2.5b, A$21.5b, and A$2.7b respectively. Analysts note risks from product mix shifts and manufacturing cost changes, while founder control remains a key theme.Yahoo3 Australian Founder Run Stocks With Market Caps Over $2bThree Australian founder-run stocks with market caps over $2b are highlighted: Flight Centre Travel Group, Pro Medicus, and Mesoblast. Flight Centre has a market cap of A$2.49b, Pro Medicus A$21.5b, and Mesoblast A$2.6b. The article notes potential margin shifts and pricing power in each company.Simply Wall St3 Australian Founder Led Stocks With Board Independence Over 63%Three Australian founder-led stocks—Flight Centre, Pro Medicus, and Mesoblast—are profiled, each with revenue and market value figures. Flight Centre has A$1.4b leisure revenue and A$2.5b market value; Pro Medicus reports A$261.7m revenue and A$21.5b market value; Mesoblast has $120m revenue and A$2.6b market value. The article notes analyst concerns about margin pressure and execution risk.FinanzNachrichten.deBiotech-Boom: Eli Lilly wächst rasant, Amgen legt nach - und Mesoblast liefert Zelltherapie-UmsätzeEli Lilly reported Q3 2026 revenue up 39% to $24.4 billion, raising its full-year guidance to $91-92 billion. Amgen's revenue rose 8%, while Mesoblast's Ryoncil generated $28 million in Q3 2026, up 44% year-over-year, with operating cash outflow down 86%.Simply Wall StThese Australian Growth Stocks Are Top Of The Class For November 2026Emerald Resources, Mesoblast, and Pinnacle Investment Management Group are highlighted as Australian growth stocks for November 2026. Emerald generates A$612 million from its Okvau Gold Project, Mesoblast reports A$120 million in revenue, and Pinnacle generates A$110 million from funds management.Simply Wall St3 Top Australian Founder Led Stocks To Watch With Up To 58.8% ROEThree founder-led Australian stocks—Pro Medicus, Mesoblast, and Harvey Norman—are profiled, each with revenue and market cap figures. Pro Medicus generates A$261.7 million, Mesoblast $120 million, and Harvey Norman A$3 billion. The article notes Harvey Norman's profit includes over 20% from property revaluations.